A recent study by Akimoto et al. used a using a model of logistic regression to show that rosiglitazone, exenatide, liraglutide, dulaglutide and sitagliptin have a significantly lower associated risk of AD than metformin.84 Among these different drugs, GLP-1 RAs appear to have the largest potential to improve cognitive performance. This evidence concerns the gene GCG and Alzheimer disease.